NVO - Novo Nordisk A/S
| Previous Close | 48.66 |
| Open | 48.88 |
| Bid | 48.52 x 1800 |
| Ask | 48.53 x 900 |
| Day's Range | 48.49 - 48.86 |
| 52 Week Range | 41.23 - 52.83 |
| Volume | 336,021 |
| Avg. Volume | 1,322,477 |
| Market Cap | 115.633B |
| Beta (3Y Monthly) | 0.83 |
| PE Ratio (TTM) | 19.70 |
| EPS (TTM) | 2.46 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.25 (2.39%) |
| Ex-Dividend Date | 2019-03-22 |
| 1y Target Est | 53.90 |
- Zacks•yesterday
Alexion (ALXN) to Report Q1 Earnings: What's in the Cards?
Alexion's (ALXN) first-quarter 2019 results are likely to gain on solid performance of lead drug, Soliris. Investors will also focus on updates on pipeline candidates.
- Zacks•2 days ago
What's in Store for Bayer (BAYRY) This Earnings Season?
Bayer (BAYRY) is expected to provide pipeline updates along with its first-quarter results.
- Investopedia•5 days ago
The Top 10 Biotechnology Companies (JNJ, ROG.VX)
Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational biotechnology corporations.
- Zacks•6 days ago
Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline
Share price of Novo Nordisk (NVO) has increased year to date on strong presence in the Diabetes Care market and a solid pipeline.
- Zacks•7 days ago
Gilead Collaborates With Insitro to Develop NASH Therapies
Gilead (GILD) collaborates with data-driven company, Insitro, to harness the power of computers to discover and develop therapies for treating NASH (fatty liver).
- Zacks•7 days ago
Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal
Key highlights of the past week are collaborations and pipeline updates.
- Zacks•9 days ago
Gilead to Collaborate with Novo Nordisk for NASH Treatment
Gilead Sciences (GILD) will collaborate with Novo Nordisk to develop treatments for liver disease, NASH.
- TheStreet.com•12 days ago
Gilead Sciences Teams With Novo Nordisk for Trials of Liver Disease Drugs
in their efforts to help combat liver disease. The two companies said they will collaborate on clinical trials for medications for treating nonalcoholic steatohepatitis (NASH). "The intended clinical trial will be a proof of concept study," according to a press release from Gilead.
- Reuters•12 days ago
Novo Nordisk and Gilead team up to test fatty liver disease treatment
Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH. The clinical trial will be a study combining Novo Nordisk's semaglutide drug and Gilead's cilofexor and firsocostat for treatment of patients with Nonalcoholic steatohepatitis (NASH), Novo Nordisk, best known for its diabetes drugs, said on Friday.
- Simply Wall St.•15 days ago
Why Fundamental Investors Might Love Novo Nordisk A/S (CPH:NOVO B)
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on N...
- Zacks•21 days ago
Sangamo Rises on Positive Phase I/II Hemophilia Study Data
Sangamo (SGMO) and partner Pfizer announce encouraging data from a phase I/II study evaluating their gene therapy candidate for treating hemophilia A.
- Insider Monkey•26 days ago
Here is What Hedge Funds Think About Adobe Inc. (ADBE)
Is Adobe Inc. (NASDAQ:ADBE) a healthy stock for your portfolio? Money managers are becoming more confident. The number of long hedge fund bets moved up by 5 recently. Our calculations also showed that ADBE is among the 30 most popular stocks among hedge funds, ranking 16th. Hedge fund sentiment towards Adobe is currently at an […]
- GuruFocus.com•28 days ago
Insurance Companies Benefit the Most From Rising Insulin Prices
Without insulin, diabetes patients will die, and many simply cannot afford to keep living. Warning! GuruFocus has detected 5 Warning Sign with NVO. The finger-pointing rages between insulin manufacturers and pharmacy benefit managers, but the truth may be that neither of them are responsible.
- Insider Monkey•29 days ago
Novo Nordisk A/S (NVO): Hedge Funds Are Snapping Up
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]
- Simply Wall St.•last month
Novo Nordisk A/S (CPH:NOVO B): Ex-Dividend Is In 4 Days
If you are interested in cashing in on Novo Nordisk A/S's (CPH:NOVO B) upcoming dividend of ø5.15 per share, you only have 4 days left to buy the shares beforeRead More...
- Motley Fool•2 months ago
REVIEWAPALOOZA!: 5-Stock Samplers
Learning more about picking, about scoring, and about holding yourself accountable.
- Zacks•2 months ago
Lilly to Bring Half-Priced Version of Popular Humalog Insulin
Eli Lilly (LLY) plans to launch a cheaper version of its popular insulin, Humalog amid increasing pressure to lower drug costs.
- Zacks•2 months ago
What's in the Cards for Aeterna (AEZS) This Earnings Season?
Aeterna (AEZS) growth hormone deficiency test, Macrilen, to drive revenues in the fourth quarter.
- PR Newswire•2 months ago
Novo Nordisk files for a label update for Fiasp® to the EMA and the FDA seeking approval for use in children and adolescents
PLAINSBORO, N.J., March 1, 2019 /PRNewswire/ -- Novo Nordisk today announced that it recently submitted label updates to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for Fiasp® (insulin aspart injection) 100 u/mL, seeking approval for use as a new mealtime insulin for children and adolescents with type 1 diabetes. Fiasp® is currently approved to control high blood sugar in adults with diabetes. Managing diabetes around mealtimes can be hard1, with parents of young children with type 1 diabetes reporting that this was one of the most problematic areas2.
- Zacks•2 months ago
Ophthotech's (OPHT) Q4 Loss Wider, Gene Therapy in Focus
Ophthotech (OPHT) reports wider-than-expected loss in the fourth quarter. It boosts gene therapy pipeline through new agreements and acquisitions.
Motley Fool•2 months agoStrongbridge Biopharma plc (SBBP) Q4 2018 Earnings Conference Call Transcript
SBBP earnings call for the period ending December 31, 2018.
- Zacks•2 months ago
Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates
Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
- Zacks•2 months ago
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
Sector ETF report for PPH
- Zacks•2 months ago
Novo Nordisk Gets FDA Nod for Haemophilia Drug Esperoct
Novo Nordisk (NVO) clinches the FDA approval for its biologics license application in favor of Esperoct to treat adults and children suffering haemophilia A.
